The Lymphoid Tissue Pharmacology of Antiretroviral Drugs
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
Antiretroviral drugs (ARVs) with enhanced LT penetration characteristics in vitro and in
macaques will translate into an ARV regimen with increased LN and GALT concentrations and a
faster decay and more potent suppression of HIV replication in LT in HIV-infected persons.
Objectives:
1. Determine lymph nodes (LN) and gut-associated lymphoid tissue (GALT) pharmacokinetics
(PK) in HIV-infected persons on an antiretroviral drug (ARV) regimen.
2. Determine virological responses of antiretroviral therapy in plasma, peripheral blood
mononuclear cells (PBMCs) and lymphoid tissue (LT).
Details
Lead Sponsor:
University of Nebraska
Collaborators:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute